Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 4000 results
Immune Pharma expands immuno-dermatology development portfolio
Immune Pharmaceuticals has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclosporine A.
Drug Research > Drug Discovery & Development > News
Medicines for psoriasis and hepatitis C accepted for use in Scotland by SMC
The Scottish Medicines Consortium (SMC) has today published advice accepting four new medicines for use in NHS Scotland.
Drug Research > Drug Discovery & Development > News
Tillotts and Numab partner for TNF-Alpha Blockers for Inflammatory Bowel
Tillotts Pharma and Numab have entered into an exclusive global licensing agreement to develop and commercialize new antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD).
Drug Research > Drug Discovery & Development > News
India and Netherlands sign MoU to develop vaccines
By PBR Staff Writer
India and Netherlands have signed a memorandum of understanding (MoU) for development of vaccines.
Drug Research > Drug Discovery & Development > News
Lilly presents positive data from BIL phase III clinical trial program
By EBR Staff Writer
Eli Lilly has presented positive data from the Phase III clinical trial program of its basal insulin peglispro (BIL) in reducing HbA1c in people with type 2 diabetes.
Drug Research > Drug Discovery & Development > News
Parion Sciences licenses ENaC inhibitors to Vertex
By PBR Staff Writer
Vertex Pharmaceuticals and Parion Sciences have entered into collaboration for the development of investigational epithelial sodium channel (ENaC) inhibitors to treat cystic fibrosis (CF) and other pulmonary diseases.
Drug Research > Drug Discovery & Development > News
Astellas reports Phase I/II trial data of ASP2215 to treat patients with AML
Astellas Pharma has announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's (ASCO) annual meeting in Chicago.
Drug Research > Drug Discovery & Development > News
Exelixis releases positive results from Phase II trial of lung cancer drug cabozantinib
By PBR Staff Writer
US-based biopharmaceutical firm Exelixis has reported positive results from a Phase II clinical trial (Study E1512) evaluating cabozantinib to treat EGFR wild-type non-small cell lung cancer (NSCLC).
Drug Research > Drug Discovery & Development > News
Tesaro, Merck to conduct Phase I/II trial of Niraparib and Keytruda for breast and ovarian cancers
By PBR Staff Writer
US-based oncology-focused biopharmaceutical firm Tesaro has collaborated with Merck to evaluate the combination of niraparib plus Keytruda (pembrolizumab), in a Phase I/II clinical trial to treat patients with triple negative breast cancer or ovarian cancer.
Drug Research > Drug Discovery & Development > News
Pfizer reports positive Phase III trial results of palbociclib in patients with HR+, HER2- metastatic breast cancer
Pfizer announced study results demonstrating palbociclib in combination with fulvestrant was superior to treatment with a standard of care, fulvestrant, by significantly extending progression-free survival (PFS) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease has progressed during or after endocrine therapy.
Drug Research > Drug Discovery & Development > News
Water Street enters into pharmaceutical development partnership
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced that it has formed a pharmaceutical development partnership with one of the world's leading global health care companies.
Drug Research > Drug Discovery & Development > News
Visterra, A*STAR to develop monoclonal antibody VIS513 to treat dengue
By PBR Staff Writer
US-based biotechnology firm Visterra and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research (A*STAR), Singapore, have collaborated to further the development of VIS513, Visterra’s neutralizing antibody to treat dengue fever.
Drug Research > Drug Discovery & Development > News
R-Tech Ueno completes Phase I single-dose trial for new VAP-1 Inhibitor RTU-1096
By PBR Staff Writer
Japan-based pharmaceutical venture business R-Tech Ueno has completed the Phase I single-dose clinical trial for the new molecular entity RTU-1096, a vascular adhesion protein-1 (VAP-1) inhibitor having anti-inflammatory and immunomodulatory effects.
Drug Research > Drug Discovery & Development > News
Regeneron, Sanofi report positive topline results from Phase III trials with sarilumab in patients with rheumatoid arthritis
Regeneron Pharmaceuticals, and Sanofi announced that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Drug Research > Drug Discovery & Development > News
SignalRx gets STTR grant from NIH to develop dual PI3 kinase/bromodomain inhibitors as anticancer agents
SignalRx Pharmaceuticals, focused on developing more effective oncology drugs though molecular design imparting selective multiple target inhibition, announced that it has received non-dilutive funding to advance the preclinical development of unique small molecule inhibitors designed to inhibit multiple critical cancer targets.
Drug Research > Drug Discovery & Development > News
61-75 of 4000 results